These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 20623989)
1. CpG oligodeoxynucleotides as TLR9 agonists: therapeutic application in allergy and asthma. Gupta GK; Agrawal DK BioDrugs; 2010 Aug; 24(4):225-35. PubMed ID: 20623989 [TBL] [Abstract][Full Text] [Related]
2. Eat dirt: CpG DNA and immunomodulation of asthma. Kline JN Proc Am Thorac Soc; 2007 Jul; 4(3):283-8. PubMed ID: 17607014 [TBL] [Abstract][Full Text] [Related]
3. CpG ODNs treatments of HIV-1 infected patients may cause the decline of transmission in high risk populations - a review, hypothesis and implications. Becker Y Virus Genes; 2005 Mar; 30(2):251-66. PubMed ID: 15744581 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic applications of synthetic CpG oligodeoxynucleotides as TLR9 agonists for immune modulation. Jurk M; Vollmer J BioDrugs; 2007; 21(6):387-401. PubMed ID: 18020622 [TBL] [Abstract][Full Text] [Related]
5. Toll-like receptor 9 activation with CpG oligodeoxynucleotides for asthma therapy. Kline JN; Krieg AM Drug News Perspect; 2008 Oct; 21(8):434-9. PubMed ID: 19034349 [TBL] [Abstract][Full Text] [Related]
6. Use of CpG oligonucleotides in treatment of asthma and allergic disease. Fonseca DE; Kline JN Adv Drug Deliv Rev; 2009 Mar; 61(3):256-62. PubMed ID: 19167442 [TBL] [Abstract][Full Text] [Related]
7. Therapeutic potential of Toll-like receptor 9 activation. Krieg AM Nat Rev Drug Discov; 2006 Jun; 5(6):471-84. PubMed ID: 16763660 [TBL] [Abstract][Full Text] [Related]
8. CpG oligodeoxynucleotides as TLR9 agonists: therapeutic applications in cancer. Murad YM; Clay TM BioDrugs; 2009; 23(6):361-75. PubMed ID: 19894778 [TBL] [Abstract][Full Text] [Related]
9. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Vollmer J; Krieg AM Adv Drug Deliv Rev; 2009 Mar; 61(3):195-204. PubMed ID: 19211030 [TBL] [Abstract][Full Text] [Related]
10. Immunostimulatory Properties of Lipid Modified CpG Oligonucleotides. Yu C; An M; Li M; Liu H Mol Pharm; 2017 Aug; 14(8):2815-2823. PubMed ID: 28686452 [TBL] [Abstract][Full Text] [Related]
11. Immunostimulatory Activities of CpG-Oligodeoxynucleotides in Teleosts: Toll-Like Receptors 9 and 21. Lai CY; Yu GY; Luo Y; Xiang R; Chuang TH Front Immunol; 2019; 10():179. PubMed ID: 30800129 [TBL] [Abstract][Full Text] [Related]
12. CpG oligodeoxynucleotide nanomedicines for the prophylaxis or treatment of cancers, infectious diseases, and allergies. Hanagata N Int J Nanomedicine; 2017; 12():515-531. PubMed ID: 28144136 [TBL] [Abstract][Full Text] [Related]
14. CpG oligodeoxynucleotides block human immunodeficiency virus type 1 replication in human lymphoid tissue infected ex vivo. Schlaepfer E; Audigé A; von Beust B; Manolova V; Weber M; Joller H; Bachmann MF; Kundig TM; Speck RF J Virol; 2004 Nov; 78(22):12344-54. PubMed ID: 15507621 [TBL] [Abstract][Full Text] [Related]
15. Structure-dependent immunostimulatory effect of CpG oligodeoxynucleotides and their delivery system. Hanagata N Int J Nanomedicine; 2012; 7():2181-95. PubMed ID: 22619554 [TBL] [Abstract][Full Text] [Related]
16. Immunotherapy of asthma using CpG oligodeoxynucleotides. Kline JN Immunol Res; 2007; 39(1-3):279-86. PubMed ID: 17917072 [TBL] [Abstract][Full Text] [Related]
17. Common human Toll-like receptor 9 polymorphisms and haplotypes: association with atopy and functional relevance. Berghöfer B; Frommer T; König IR; Ziegler A; Chakraborty T; Bein G; Hackstein H Clin Exp Allergy; 2005 Sep; 35(9):1147-54. PubMed ID: 16164440 [TBL] [Abstract][Full Text] [Related]
19. Modifications incorporated in CpG motifs of oligodeoxynucleotides lead to antagonist activity of toll-like receptors 7 and 9. Yu D; Wang D; Zhu FG; Bhagat L; Dai M; Kandimalla ER; Agrawal S J Med Chem; 2009 Aug; 52(16):5108-14. PubMed ID: 19650625 [TBL] [Abstract][Full Text] [Related]